A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

This Phase 2 study evaluates a topical gel called TCP-25 for treating open wounds in people with dystrophic or junctional epidermolysis bullosa (DEB or JEB) — rare genetic skin conditions where the skin blisters and wounds easily. The gel is applied to matched wound pairs, with one wound receiving the active treatment and the other receiving a placebo gel, to compare healing outcomes directly in the same person. Patients aged 4 and older with a confirmed genetic diagnosis of DEB or JEB who are not currently on systemic antibiotics may be eligible. Participation involves clinic visits every 2 weeks for 8 weeks to apply the gel and photograph wounds, followed by a safety phone call at 2 weeks after treatment ends. This summary was generated by AI to help patients understand the study in plain language.